Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Posted by Stanley Muller on Nov 1st, 2026

Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the five research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $3.83.

A number of research firms have recently weighed in on NAUT. Leerink Partners began coverage on Nautilus Biotechnology in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 target price for the company. Zacks Research upgraded Nautilus Biotechnology to a “hold” rating in a report on Wednesday, September 30th. Weiss Ratings upgraded Nautilus Biotechnology from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday. Finally, Roth Capital initiated coverage on Nautilus Biotechnology in a research note on Tuesday, September 29th. They issued a “buy” rating and a $3.50 price target on the stock.

Read Our Latest Research Report on Nautilus Biotechnology

Nautilus Biotechnology Stock Down 13.1%

Nautilus Biotechnology stock opened at $2.73 on Tuesday. The company has a market capitalization of $347.72 million, a PE ratio of -5.93 and a beta of 0.73. The firm has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $2.11. Nautilus Biotechnology has a twelve month low of $0.84 and a twelve month high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.21 million. As a group, equities analysts expect that Nautilus Biotechnology will post -0.50 earnings per share for the current fiscal year.

Institutional Trading of Nautilus Biotechnology

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Nautilus Biotechnology during the 2nd quarter valued at $5,025,000. Susquehanna International Group LLP grew its holdings in Nautilus Biotechnology by 1,710.9% in the 2nd quarter. Susquehanna International Group LLP now owns 890,949 shares of the company’s stock worth $1,666,000 after acquiring an additional 841,749 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Nautilus Biotechnology by 15.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 329,123 shares of the company’s stock worth $1,274,000 after acquiring an additional 43,684 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Nautilus Biotechnology by 2.2% in the 1st quarter. Renaissance Technologies LLC now owns 265,700 shares of the company’s stock worth $1,031,000 after acquiring an additional 5,800 shares during the last quarter. Finally, Corient Private Wealth LP purchased a new position in shares of Nautilus Biotechnology in the second quarter valued at about $308,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

(Get Free Report)

Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.

The company’s principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.